Table 4.
Association of polymorphisms in antioxidative genes with NYHA class and LVEF reduction.
| NYHA | LVEF reduction | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | Genotype | Class 1, N (%) | Class 2, N (%) | OR (95% CI) | P | OR (95% CI)adj | P adj | No, N (%) | Yes, N (%) | OR (95% CI) | P |
| PON1 rs854560 | AA | 33 (78.6) | 9 (21.4) | Reference | 38 (90.5) | 4 (9.5) | Reference | ||||
| AT+TT | 51 (86.4) | 8 (13.6) | 0.58 (0.20-1.64) | 0.301 | 0.61 (0.19-1.99) | 0.416 | 54 (91.5) | 5 (8.5) | 0.88 (0.22-3.49) | 0.885 | |
| PON1 rs662 | AA | 44 (81.5) | 10 (18.5) | Reference | 50 (92.6) | 4 (7.4) | Reference | ||||
| AG+GG | 40 (85.1) | 7 (14.9) | 0.77 (0.27-2.22) | 0.628 | 0.88 (0.27-2.84) | 0.832 | 42 (89.4) | 5 (10.6) | 1.49 (0.38-5.90) | 0.572 | |
| GSTP1 rs1138272 | CC | 69 (83.1) | 14 (16.9) | Reference | 75 (90.4) | 8 (9.6) | Reference | ||||
| CT+TT | 15 (83.3) | 3 (16.7) | 0.99 (0.25-3.87) | 0.984 | 0.88 (0.20-3.92) | 0.862 | 17 (94.4) | 1 (5.6) | 0.55 (0.07-4.71) | 0.586 | |
| GSTP1 rs1695 | GG | 36 (81.8) | 8 (18.2) | Reference | 38 (86.4) | 6 (13.6) | Reference | ||||
| GA+AA | 48 (84.2) | 9 (15.8) | 0.84 (0.30-2.40) | 0.750 | 0.84 (0.26-2.74) | 0.773 | 54 (94.7) | 3 (5.3) | 0.35 (0.08-1.50) | 0.157 | |
| CAT rs1001179 | GG | 58 (90.6) | 6 (9.4) | Reference | 58 (90.6) | 6 (9.4) | Reference | ||||
| GA+AA | 26 (70.3) | 11 (29.7) | 4.09 (1.37-12.25) | 0.012 | 4.14 (1.22-14.09) | 0.023 | 34 (91.9) | 3 (8.1) | 0.85 (0.20-3.63) | 0.830 | |
| HIF1A rs1154965 | CC | 71 (80.7) | 17 (19.3) | Reference | 81 (92.0) | 7 (8.0) | Reference | ||||
| CT+TT | 13 (100.0) | 0 (0.0) | / | 0.118∗ | 11 (84.6) | 2 (15.4) | 2.10 (0.39-11.44) | 0.389 | |||
Adj: adjusted for hyperlipidemia and body mass index. ∗calculated using Fisher's exact test. CI: confidence interval; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; OR: odds ratio.